DxS Appoints David Jackson as Vice President of Business Development and Licensing

18-Aug-2009 - United Kingdom

DxS Ltd has announced the appointment of Dr. David Jackson as Vice President of business development and Licensing. Dr. Jackson will be responsible for planning and executing business development efforts for the companion diagnostics and technology licensing business units of DxS and will be based in the US.

Dr. Jackson was most recently with Response Genetics, Inc. as Executive Vice President and has extensive consulting experience in personalized medicine. Before this he was president and chief operating officer at of CryoFluor Therapeutics. During his career Jackson has held positions including private and public company investment analyst, product and corporate development, and Intellectual Property management roles. He holds a PhD in Physiology and Medicine from Boston University School of Medicine, is trained as a US Patent Agent and holds several US securities licenses.

Other news from the department people

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

See the theme worlds for related content